Publications by the researcher in collaboration with Francisco Abad Santos (43)

2022

  1. Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives

    Pharmaceutics, Vol. 14, Núm. 3

  2. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

    Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 483-494

2021

  1. PriME-PGX: La Princesa university hospital multidisciplinary initiative for the implementation of pharmacogenetics

    Journal of Clinical Medicine, Vol. 10, Núm. 17

  2. Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial

    Human Psychopharmacology, Vol. 36, Núm. 1, pp. 1-12

  3. Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics

    Advances in Therapy, Vol. 38, Núm. 2, pp. 1035-1054

  4. Influence of Genetic Polymorphisms on the Response to Tramadol, Ibuprofen, and the Combination in Patients With Moderate to Severe Pain After Dental Surgery

    Clinical Therapeutics, Vol. 43, Núm. 5, pp. e86-e102

  5. Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers

    Biomedicine and Pharmacotherapy, Vol. 133

  6. High-Fat Breakfast Increases Bioavailability of Albendazole Compared to Low-Fat Breakfast: Single-Dose Study in Healthy Subjects

    Frontiers in Pharmacology, Vol. 12

  7. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling

    Clinical Pharmacokinetics, Vol. 60, Núm. 2, pp. 261-270

  8. Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin

    Frontiers in Pharmacology, Vol. 12

2020

  1. Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19)

    Clinical and Translational Science, Vol. 13, Núm. 6, pp. 1023-1033

  2. Author’s Response to: ‘Letter to the Editor in Response to: “Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally”’

    Advances in Therapy

  3. The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 10, pp. 2051-2062

  4. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics

    Pharmacogenomics, Vol. 21, Núm. 10, pp. 663-675

  5. Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers

    Pharmacogenomics Journal, Vol. 20, Núm. 2, pp. 235-245

  6. Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers

    Basic and Clinical Pharmacology and Toxicology, Vol. 126, Núm. 3, pp. 236-246

  7. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates

    Biomedicines, Vol. 8, Núm. 4

  8. Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole

    BMC Pharmacology and Toxicology, Vol. 21, Núm. 1

  9. Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran

    Advances in Therapy, Vol. 37, Núm. 8, pp. 3537-3550

  10. Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects

    Clinical Drug Investigation, Vol. 40, Núm. 7, pp. 617-628